Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT01887457
Other study ID # 13_DOG06_172
Secondary ID 2013-002578-34
Status Suspended
Phase Phase 2
First received June 7, 2013
Last updated October 6, 2015
Start date September 2014
Est. completion date December 2016

Study information

Verified date October 2015
Source Christie Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This is a trial to determine whether giving a patient a tailored dose of voriconazole is safe and effective.


Description:

Invasive fungal infections are a major cause of morbidity and mortality in patients with haematological malignancy and haematopoietic stem cell transplantation.

Voriconazole is routinely used as a first-line agent for the treatment of invasive aspergillosis, invasive fusariosis and scedosporiosis. Voriconazole has extreme pharmacokinetic variability. Adult patients with a trough concentration of < 1 mg/L have a lower probability of clinical response whereas patients with trough concentrations > 6 mg/L a higher probability of toxicity.

Therapeutic drug monitoring for dose adjustment is advocated but there are no algorithms that enable voriconazole dosage to be reliably adjusted to achieve desired trough concentrations in a timely and optimally precise manner.

Novel ways to deliver optimised antifungal therapy are urgently required and this trial will evaluate whether giving a patients a tailored dose of voriconazole is safe and effective.

Plasma concentrations will be taken in real time and inputted in dose software that will calculate an optimum dose for the required trough concentration of 1-3 mg/L.

The software has been developed using data from phase I and III trials of voriconazole.


Recruitment information / eligibility

Status Suspended
Enrollment 33
Est. completion date December 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Any adult =18 years old

- Patients where a new course of voriconazole is indicated for suspected or confirmed invasive aspergillosis or other serious fungal infections that is deemed by the treating physician to be susceptible to voriconazole

- Patients must have venous access to permit the administration of voriconazole and enable the procurement of multiple plasma samples to measure voriconazole concentrations.

- Estimated creatinine clearance = 50 mL/min

- Able to give written informed consent

- Considered fit to receive the trial treatment

- Able to remain in the hospital for at least 5 days or until they complete their trial treatment

- Female patients must satisfy the investigator that they are not pregnant, or are not of childbearing potential, or are using adequate contraception

- Men must also use adequate contraception

Exclusion Criteria:

- Patients with an estimated creatinine clearance < 50 mL/minute (this precludes the use of intravenous voriconazole)

- Patients receiving any form of renal replacement therapy i.e. haemodialysis or haemofiltration

- Patients with hepatic insufficiency

- Female patients that are pregnant, breast feeding or planning pregnancy during the study

- Past history of intolerance to voriconazole

- Age <18

- Evidence of a clinically relevant fungal isolate that is resistant to voriconazole

- QT prolongation on ECG

- Use of other medications that contraindicate the use of voriconazole

- Patients receiving any other medications that are contraindicated with the use of voriconazole i.e. terfenadine, long acting barbiturates, ergot alkaloids, etc. (Refer to SMPC). Only patients on rifampicin, rifabutin, phenytoin, and carbamazepine would have voriconazole precluded. Voriconazole influences with the pharmacokinetics of many additional agents- (see SMPC)- most importantly anti-rejection compounds- cyclosporine, tacrolimus]

- Uncontrolled cardiac, respiratory or other disease or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent.

- Hypersensitivity to Voriconazole, its excipients or other triazoles

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
VFEND
voriconazole will be administered in iv form

Locations

Country Name City State
United Kingdom The Christie NHS Foundation Trust Manchester

Sponsors (2)

Lead Sponsor Collaborator
Brynn Chappell Christie Hospital NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose adjustment success Dose adjustment success will be evaluated by plasma trough concentration on day 5, successful dose adjustment is defined as a trough concentration of 1-3 mg/L of voriconazole. Day 5 of treatment No
Secondary Mortality of patients To examine the mortality of patients receiving individualised voriconazole dosing 35 Day after starting treatment Yes
Secondary Toxicity To evaluate the adverse events that are attributable to voriconazole as assessed by CTCAE v4. Day 5 of treatment and 35 day follow-up Yes
See also
  Status Clinical Trial Phase
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Enrolling by invitation NCT01617759 - Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
Terminated NCT03905447 - The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. Phase 2
Recruiting NCT04744454 - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Completed NCT02715570 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 Phase 1
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Completed NCT04935463 - Mucormycosis in COVID-19
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00473252 - Surveillance of Fungal Infections During Construction Activity N/A
Completed NCT00037206 - A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Phase 2/Phase 3
Completed NCT04818853 - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Recruiting NCT06135597 - Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Terminated NCT02646800 - Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Phase 4
Completed NCT00854607 - An Observational Study of Fungal Biomarkers (MK-0000-089) N/A
Completed NCT00388167 - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Phase 4
Completed NCT05065658 - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Completed NCT00005912 - Voriconazole to Prevent Systemic Fungal Infections in Children Phase 1
Completed NCT04431804 - THYME AND CARVACROLL Nanoparticle Effect on Fungi

External Links